MLYS Stock Analysis: Buy, Sell, or Hold?
MLYS - Mineralys Therapeutics, Inc. Common Stock
$25.65
-0.10 (-0.39%)
▼
5d:
+0.04%
30d:
-5.0%
90d:
-15.15%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When MLYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: MLYS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: MLYS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: MLYS is currently trading at $25.65, which is considered oversold relative to its 30-day fair value range of $26.09 to $27.28.
Technical Outlook: Technically, MLYS is in a downtrend. The price is currently testing key support at $25.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MLYS scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $48.50 (+89.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MLYS is in a downtrend. The price is currently testing key support at $25.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MLYS scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $48.50 (+89.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$26.09 -
$27.28
Company Quality Score
42/100
(HOLD)
Options IV Signal
3th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
Protect Your Profits
Holding MLYS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 3th percentile)
- BEARISH: Weak technical setup (16/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 89.1% below Wall St target ($48.50)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$26.09 -
$27.28
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.55
(9.9%)
Support & Resistance Levels
Support Level
$25.00
Resistance Level
$28.09
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.26
Wall Street Target
$48.50
(+89.1%)
Share & Embed Analysis
Last updated: August 22, 2026 11:04 PM ET
Data refreshes hourly during market hours. Next update: 12:04 AM
Data refreshes hourly during market hours. Next update: 12:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MLYS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
David Malcom Rodman
SELL
416 shares
2026-04-17
David Malcom Rodman
SELL
6348 shares
2026-04-15
David Malcom Rodman
SELL
14058 shares
2026-04-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 40 SELL |
Advanced MLYS Option Strategies
Professional options setups generated by AI based on today's MLYS price and gamma walls.
